Intuitive Surgical (ISRG) Expected to Announce Quarterly Earnings on Tuesday

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) is anticipated to issue its quarterly earnings data after the market closes on Tuesday, April 22nd. Analysts expect the company to announce earnings of $1.71 per share and revenue of $2.19 billion for the quarter. Persons interested in listening to the company's earnings conference call can do so using this link.

Intuitive Surgical Price Performance

NASDAQ ISRG opened at $482.74 on Friday. Intuitive Surgical has a 12 month low of $364.31 and a 12 month high of $616.00. The company has a market capitalization of $171.94 billion, a price-to-earnings ratio of 75.31, a price-to-earnings-growth ratio of 5.85 and a beta of 1.55. The firm's fifty day moving average price is $522.23 and its 200 day moving average price is $532.34.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Truist Financial reduced their target price on Intuitive Surgical from $666.00 to $605.00 and set a "buy" rating for the company in a report on Monday, March 17th. Evercore ISI boosted their price objective on Intuitive Surgical from $490.00 to $530.00 in a research note on Monday, January 27th. Bernstein Bank raised their target price on shares of Intuitive Surgical from $655.00 to $700.00 and gave the stock an "overweight" rating in a research report on Monday, January 27th. Royal Bank of Canada lifted their target price on shares of Intuitive Surgical from $611.00 to $641.00 in a report on Monday, January 27th. Finally, Jefferies Financial Group increased their price target on shares of Intuitive Surgical from $475.00 to $575.00 in a research note on Monday, January 27th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat.com, Intuitive Surgical presently has a consensus rating of "Moderate Buy" and a consensus target price of $611.81.

Insider Activity

In other news, Director Amal M. Johnson sold 4,635 shares of the stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $566.60, for a total value of $2,626,191.00. Following the completion of the transaction, the director now owns 12,275 shares in the company, valued at $6,955,015. This trade represents a 27.41 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Robert Desantis sold 11,545 shares of the business's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $499.22, for a total transaction of $5,763,494.90. Following the sale, the executive vice president now directly owns 5,224 shares in the company, valued at approximately $2,607,925.28. This represents a 68.85 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 33,754 shares of company stock valued at $17,691,621 in the last three months. 0.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Intuitive Surgical

An institutional investor recently raised its position in Intuitive Surgical stock. Brighton Jones LLC grew its position in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 24.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,672 shares of the medical equipment provider's stock after buying an additional 731 shares during the quarter. Brighton Jones LLC's holdings in Intuitive Surgical were worth $1,916,000 at the end of the most recent quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.